1 / 26

New Horizons in Adjunctive Type 1 Diabetes Management With SGLT Inhibitors

Explore the potential benefits of SGLT inhibitors in managing type 1 diabetes. Discover non-insulin therapies such as pramlintide and T2DM therapies like metformin, GLP-1 RAs, and SGLT inhibitors. Learn about clinical trials and the inTandem program's results.

hnicholson
Télécharger la présentation

New Horizons in Adjunctive Type 1 Diabetes Management With SGLT Inhibitors

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. New Horizons in Adjunctive Type 1 Diabetes Management With SGLT Inhibitors

  2. Program Overview

  3. Glycemic Control in T1DM

  4. Risks Associated With T1DM

  5. Limitations of Insulin Therapy for T1DM

  6. Noninsulin Therapy for T1DM: Pramlintide

  7. T2DM Therapies for T1DM: Metformin

  8. T2DM Therapies for T1DM: GLP-1 RAs

  9. T2DM Therapies for T1DM: SGLT Inhibitors

  10. SGLT1/2 Inhibitors

  11. Potential Benefit of SGLT1/2 Inhibitors for Patients With T1DM

  12. Clinical Trials With SGLT Inhibitors for T1DM

  13. Sotagliflozin for T1DM: inTandem Program

  14. inTandem 3: Results

  15. inTandem 3: Other Efficacy Endpoints

  16. inTandem 3: Hypoglycemia and DKA

  17. inTandem 3: Insulin Dose

  18. Dapagliflozin in Patients With Inadequately Controlled T1DM: DEPICT Trials

  19. Managing DKA: Key Points for Clinicians

  20. Clinical Protocol for Managing the DKA Risk With SGLT Inhibitors

  21. Clinical Protocol for Managing the DKA Risk With SGLT Inhibitors (cont)

  22. Additional Considerations for Clinicians

  23. Conclusion

  24. Abbreviations

  25. Abbreviations (cont)

More Related